Oncolytic Viral Therapy Development Services
Oncolytic viral therapy is a method that uses natural or reprogrammed viruses to target and kill cancer cells. Alfa Cytology is a world leader in cancer therapy development. With our extensive experience and advanced platform, we can provide the best solutions for oncolytic viral therapy development.
Introduction to Oncolytic Viral Therapy
Since the first attempt to use viruses to treat tumors in the 20th century, oncolytic virus therapy has been extensively and deeply studied in cancer therapy. These viruses offer a novel therapy by selectively targeting and destroying cancer cells while preserving healthy tissue. While some viruses are less popular, many can be effectively engineered based on their infectivity and ability to carry engineered DNA or RNA fragments. In addition to the direct oncolytic effect of selective infection of lytic tumor cells, oncolytic viruses can also mediate the release of virus-associated antigens and tumor neoantigens and finally activate the anti-tumor immunity to achieve the effect of killing the tumor.
Fig.1 Multimodal mechanisms of action associated with oncolytic virus therapy. (Kaufman, H.L. & Maciorowski, D., 2021)
Oncolytic Virus Therapy Development for Different Cancer
The oncolytic virus is an anticancer agent that can replicate in lytic malignant cells without infecting healthy cells. In general, oncolytic viruses are used in cancer treatment in three main ways.
- Some oncolytic viruses can essentially exploit cellular defects that promote tumor growth.
- Some oncolytic viruses can be engineered to take advantage of tumor-specific mutations that occur frequently in antiviral defense programs or to rely on signaling pathways that are compositionally activated in tumors.
- Based on the expression of specific antigens on the surface of tumor cells.
Therefore, when developing disease-specific oncolytic virus treatment strategies, it is important to consider both cancer immunology and the characteristics of the selected virus.
Current Status of Oncolytic Viral Therapy Development
Oncolytic virus therapy has the characteristics of immunotherapy, targeted therapy, and gene therapy, and is expected to become a new generation of anti-cancer tools. Oncolytic viral therapy has been tested in clinical trials in many cancers.
Indication |
Therapeutics |
Company |
Phase |
Ovarian Cancer |
TILT-T563 (NCT05271318) |
TILT Biotherapeutics |
|
Lung Cancer |
TILT-T610 (NCT06125197) |
TILT Biotherapeutics |
|
Bladder Cancer |
MV-NIS |
Vyriad |
|
Our Services
With our specialized laboratories and development platform, Alfa Cytology provides customized, standardized, reliable, and high-quality oncolytic virus therapy development services to worldwide customers. Our services cover everything from virus engineering and cell biology to animal testing. Various types of oncolytic virus engineering systems have been established in-house to facilitate the development of oncolytic virus therapies in a shorter time and at a lower budget.
Oncolytic Virus
Construction
We thoroughly studied the properties of various viruses, taking into account their exploitability, tendency, potential function, and application, and established a specific oncolytic virus construction process for different types of viruses, such as adenovirus, herpes simplex virus, measles virus, vaccinia virus, and vesicular stomatitis virus. Alfa Cytology provides multiple types of oncolytic viruses for different tumors.
Oncolytic Virus
Engineering
By combining the main work mechanisms of oncolytic viruses, we have developed a variety of engineering methods that take full advantage of the natural properties of various viruses. With a rich background in immunotherapy development, Alfa Cytology deeply optimizes oncolytic viruses to enhance tumor targeting, tumor lysis and the effectiveness of initiating anti-cancer immunity.
Oncolytic Virus
Characterization
To ensure the comprehensiveness of the research, we design in vitro and in vivo preclinical validation studies for each oncolytic virus according to the targeted disease nature, virus characteristics, mechanism of action, etc. Based on the validation results, the oncolytic virus therapy that has been developed can be further optimized to make it safer and more effective against cancer.
Why Choose Us?
Frontier Science
Customized Services
Extensive Experience
Quality Assurance
Alfa Cytology is committed to the research and study of cancer and provides one-stop services. Our cancer experts have many years of experience in the latest therapies for oncolytic viral therapy. If you are interested in our service, please contact us for more information.
Reference
- Kaufman, H. L., & Maciorowski, D. (2021). Advancing oncolytic virus therapy by understanding the biology. Nature Reviews Clinical Oncology, 18(4), 197-198.
For research use only.
Related Services